{"filings":[{"id":1940597,"accession_number":"0001628280-26-050607","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-07-29T20:07:19+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q2 revenue up 32% to $256M; raises FY2026 guidance to $1.1-1.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $256.1M (+32% YoY); net income $43.0M ($0.36 diluted EPS) vs $35.1M ($0.29) in Q2 2025.","Lifyorli (relacorilant) generated $47.6M in first quarter of availability; over 1,300 patients started treatment.","FY2026 revenue guidance increased to $1.1-1.2 billion.","NDA for relacorilant in Cushing's syndrome resubmitted; PDUFA date December 17, 2026.","Cash and investments $544.6M at June 30, 2026, up from $515.4M at March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1112277,"accession_number":"0001193125-26-274258","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-06-17T20:36:46+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept resubmits NDA for relacorilant to FDA for Cushing's syndrome; six-month review expected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmission based on pivotal GRACE trial and Phase III GRADIENT trial data.","Includes additional analyses requested by FDA; expects six-month review cycle.","Relacorilant shows durable symptom improvement without serious adverse events like hypokalemia or pregnancy termination.","CEO states company looks forward to working with FDA toward approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":815884,"accession_number":"0001193125-26-254622","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-06-03T12:00:06+00:00","items":["8.01"],"status":"ready","headline":"DOJ declines to intervene in Corcept qui tam lawsuit; relator files amended complaint","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["DOJ filed Notice of Election to Decline Intervention on May 19, 2026 in case U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics.","DOJ, California Dept of Insurance, and named Plaintiff States all declined to intervene in the qui tam action.","Relator served an amended complaint on June 2, 2026; company intends to vigorously defend.","Allegations relate to Korlym sales, promotion, payments to HCPs, and prior authorizations (from Nov 2021 subpoena)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":721756,"accession_number":"0001628280-26-038793","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-05-28T20:04:39+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Corcept shareholders approve 8M-share increase to 2024 Incentive Award Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2024 Incentive Award Plan, adding 8,000,000 authorized shares.","All eight director nominees elected; vote totals show majority support for each.","Ernst & Young ratified as independent auditor for fiscal 2026.","Advisory vote on named executive officer compensation passed with 72.5 million 'for' votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91203,"accession_number":"0001628280-26-028892","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q1 revenue $164.9M (+5% YoY); raises 2026 guidance to $950-1050M; Lifyorli approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $164.9M, up 5% YoY from $157.2M. Net loss $31.8M vs net income $20.5M in Q1 2025 due to launch costs.","2026 revenue guidance raised to $950-$1,050M (from prior range).","FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026; NCCN preferred regimen.","Cash and investments $515.4M at March 31, 2026. Expect return to profitability in Q2 2026.","ROSELLA trial results published in The Lancet; BELLA, SYNERGY, MONARCH, DAZALS trials ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":164903000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101169,"accession_number":"0001193125-26-123543","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.","Approval based on ROSELLA trial: 35% reduction in risk of death (HR 0.65, median OS 16.0 vs 11.9 months).","Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA).","Most common adverse reactions: decreased hemoglobin, neutrophils, fatigue, nausea, diarrhea, rash, decreased appetite."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101168,"accession_number":"0001628280-26-011080","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q4 revenue $202.1M, FY2025 $761.4M; guides FY2026 revenue $900M-$1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $202.1M (vs $181.9M Q4 2024); full-year revenue $761.4M (vs $675.0M in 2024).","Diluted EPS: Q4 $0.20, FY2025 $0.82 (vs Q4 2024 $0.26, FY2024 $1.23). Net income declined due to stock repurchases and operational costs.","Cash and investments $532.4M at Dec 31, 2025; spent $245.9M on stock repurchases in 2025.","FY2026 revenue guidance $900M-$1B; expects continued Cushing's syndrome business growth.","PDUFA date July 11, 2026 for relacorilant NDA in platinum-resistant ovarian cancer; FDA engaged after CRL for Cushing's NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":761407000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101167,"accession_number":"0001193125-26-059551","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.","Ruling affirms December 2023 District of New Jersey verdict; Corcept will consider further judicial review.","CEO Joseph Belanoff expressed disappointment and said company will vigorously defend its rights.","Patents cover methods used in treating Cushing's syndrome; generic entry would weaken Korlym's market exclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101166,"accession_number":"0001193125-26-018704","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept's ROSELLA Phase 3 trial meets overall survival endpoint; 35% risk reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Relacorilant + nab-paclitaxel reduced risk of death by 35% vs. nab-paclitaxel alone (HR 0.65, p=0.0004).","Median OS 16.0 months vs. 11.9 months (4.1-month improvement); both dual primary endpoints met.","NDA under FDA review with PDUFA date of July 11, 2026; MAA under EMA review.","Relacorilant well-tolerated without increased safety burden; no biomarker selection required.","Trial enrolled 381 patients across US, Europe, South Korea, Brazil, Argentina, Canada, Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117515,"accession_number":"0001193125-25-338184","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Corcept's relacorilant NDA in hypercortisolism","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA concluded benefit-risk assessment unfavorable without additional effectiveness evidence.","Pivotal GRACE trial met primary endpoint; GRADIENT trial provided confirmatory evidence.","CEO Joseph Belanoff expressed surprise and disappointment; plans to meet with FDA.","Relacorilant was under review for hypertension secondary to hypercortisolism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117514,"accession_number":"0001628280-25-048814","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.","Modified 2025 revenue guidance to $800-850M, citing capacity constraints at prior specialty pharmacy.","Cash and investments $524.2M; repurchased $50.6M in stock during Q3.","NDA for relacorilant in hypercortisolism PDUFA Dec 30, 2025; NDA for ovarian cancer PDUFA July 11, 2026.","New oncology trials starting: Phase 2 in earlier-stage ovarian, endometrial, cervical, pancreatic cancers; Phase 1b for nenocorilant with immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":559282000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117513,"accession_number":"0001193125-25-237834","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Corcept terminates distribution agreement with Optime Care, effective Jan 8, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice of termination of Distribution Services Agreement with Optime Care given Oct 10, 2025; effective Jan 8, 2026.","Optime had been specialty pharmacy distributor for Korlym and authorized generic mifepristone.","Exclusive provider status ended Sept 15, 2025; termination is for convenience under 90-day notice provision.","Original agreement dated Aug 4, 2017, amended and restated Apr 1, 2024, with term through Mar 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117512,"accession_number":"0001193125-25-231963","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Gillian Cannon resigns from Corcept board; consulting agreement signed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gillian Cannon resigned from the Board effective October 10, 2025, with no disagreement over operations or policies.","Company and Cannon entered consulting agreement from effective date until 2026 annual stockholder meeting.","Consulting fee: $5,708.33 per month; previously awarded stock options continue vesting per original schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133931,"accession_number":"0001193125-25-199706","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Corcept's NDA for relacorilant in platinum-resistant ovarian cancer; PDUFA July 11, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted Corcept's NDA for relacorilant in platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.","NDA based on positive Phase 3 ROSELLA and Phase 2 data showing improved PFS and OS without biomarker selection.","Relacorilant plus nab-paclitaxel was well-tolerated; adverse events similar to nab-paclitaxel monotherapy.","CEO Joseph Belanoff: 'FDA acceptance brings us closer to offering a much-needed treatment option for this dire disease.'","Relacorilant may redefine platinum-resistant ovarian cancer treatment, Corcept states."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133930,"accession_number":"0001628280-25-036999","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.","Modified 2025 revenue guidance to $850-900M; cash & investments $515M after $115.4M buyback.","NDA for relacorilant in hypercortisolism (PDUFA Dec 30, 2025); NDA submitted for ovarian cancer.","DAZALS: dazucorilant 300mg showed 84% reduced death risk (HR 0.16, p=0.0009); regulatory discussions.","Record new prescribers/patients; vendor capacity constraints offset demand; second pharmacy coming online."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":351644000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133929,"accession_number":"0001193125-25-158454","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept submits NDA for relacorilant as treatment for platinum-resistant ovarian cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA submitted to FDA for relacorilant plus nab-paclitaxel, based on Phase 3 ROSELLA and Phase 2 trials.","Improved progression-free and overall survival vs nab-paclitaxel monotherapy; no biomarker selection needed.","Relacorilant well-tolerated; adverse events similar to monotherapy, no increased safety burden.","CEO notes this is Corcept's second NDA before FDA; relacorilant also under review for hypercortisolism.","Company preparing launch once approved; oncology and endocrinology units in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150672,"accession_number":"0001628280-25-031624","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Corcept shareholders elect nine directors, ratify Ernst & Young, approve executive comp at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with substantial support; David Mahoney received 62.7M for, 14.7M withheld.","Ernst & Young ratified as auditor for FY 2025 with 90.5M votes for, 1.5M against.","Advisory vote on executive compensation approved with 72.9M for, 4.2M against, 14.9M broker non-votes.","Total shares voted: 92.3M out of 106.0M eligible shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150671,"accession_number":"0001628280-25-022167","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q1 revenue $157.2M (+7%); FY25 guide $900-950M reaffirmed; relacorilant & dazucorilant updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.","Reiterated FY 2025 revenue guidance $900-950M; cash/investments $570.8M (down from $603.2M due to buybacks).","Relacorilant NDA for Cushing's under FDA review with PDUFA Dec 30, 2025; NDA for ovarian cancer expected Q3 2025.","Phase 3 ROSELLA trial met PFS and OS endpoints; results to be presented at ASCO June 2025.","Dazucorilant ALS trial missed primary endpoint; exploratory survival benefit at 1yr (HR 0.16, p=0.0009); seeking regulatory input."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":157214000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169623,"accession_number":"0001193125-25-067871","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.","Interim OS also positive: median OS 16.0 vs 11.5 months (HR 0.69, p=0.012).","Relacorilant well-tolerated; no new safety signals; safety comparable between groups.","Company expects to submit NDA in Q3 2025 and MAA shortly thereafter.","Trial enrolled 381 patients globally; biomarker selection not required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169622,"accession_number":"0001193125-25-044123","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Corcept's NDA for relacorilant in Cushing's syndrome; PDUFA Dec 30, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA filed relacorilant NDA for endogenous hypercortisolism (Cushing's syndrome).","PDUFA target action date set for December 30, 2025.","NDA supported by positive GRACE, GRADIENT, and Phase 2 trial results.","No drug-induced adrenal insufficiency, hypokalemia, or QT prolongation observed in trials.","CEO states relacorilant has potential to become new standard of care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169621,"accession_number":"0001628280-25-008131","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).","FY net income $141.2M ($1.23 diluted EPS) vs $106.1M ($0.94) in 2023.","2025 revenue guidance $900-$950M; cash and investments $603.2M at Dec 31, 2024.","NDA submitted for relacorilant for hypercortisolism; ROSELLA Phase 3 data expected this quarter.","DAZALS Phase 2 in ALS missed primary endpoint; showed survival benefit (0 vs 5 deaths at 24 weeks, p=0.02)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":675040000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186683,"accession_number":"0001193125-24-286917","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept submits NDA for relacorilant to treat Cushing's syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.","No drug-induced adrenal insufficiency, hypokalemia, QT prolongation, or progesterone receptor effects seen.","CEO Joseph Belanoff states relacorilant has potential to become standard of care for hypercortisolism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186682,"accession_number":"0001628280-24-044318","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q3 revenue $182.5M (+48% YoY); guides FY2024 to $675-700M; positive GRADIENT results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $182.5M (+48% YoY); diluted EPS $0.41 vs $0.28; net income $47.2M.","FY2024 revenue guidance raised to $675-700M from $640-670M; strong Korlym prescriber and patient growth.","Cash and investments $547.6M; repurchased 870K shares for $23.4M in Q3.","Phase 3 GRADIENT in Cushing's syndrome: significant improvements in BP, glucose, weight vs placebo; no hypokalemia or endometrial hypertrophy.","NDA for relacorilant in Cushing's to be submitted this quarter; ROSELLA (ovarian cancer) and DAZALS (ALS) data expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":493150000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203240,"accession_number":"0001628280-24-033281","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.","2024 revenue guidance raised to $640-670M from $620-650M.","Cash and investments $492.5M at June 30, up from $451M at March 31.","NDA submission for relacorilant in Cushing's syndrome expected Q4; late-stage trial results (ROSELLA, GRADIENT, DAZALS) due by year-end.","Record number of new Korlym prescribers and patients; hypercortisolism screening expanding."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":310604000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219578,"accession_number":"0001628280-24-024936","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Corcept Therapeutics shareholders approve 2024 Incentive Award Plan adding 8M new shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Plan replaces 2012 plan; total shares authorized = 8M new + 4,073,955 carryover + lapsed awards.","All 9 director nominees elected; vote range 56.9M to 65.6M for (excluding broker non-votes).","Ernst & Young ratified as auditor for FY2024: 86.6M for, 1.7M against.","Advisory say-on-pay approved: 64.5M for, 1.0M against; 22.5M broker non-votes.","2024 Plan passed with 47.0M for, 18.7M against; 22.5M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219577,"accession_number":"0001628280-24-019607","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.","2024 revenue guidance raised to $620-650M from $600-630M.","Cash and investments $451.0M at March 31, 2024.","GRACE open-label phase showed significant improvements; NDA for relacorilant in Cushing's expected this quarter.","Enrollment completed in GRADIENT, CATALYST, ROSELLA, DAZALS; data expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":146808000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219576,"accession_number":"0001193125-24-098492","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Corcept subleases 50,632 sq ft in Redwood City from Zuora for six years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease with Zuora for ~50,632 rentable sq ft at 101 Redwood Shores Pkwy, Redwood City.","Base rent avg $1.4M/yr plus $240K/yr shared amenities; term July 1, 2024 to June 30, 2030.","Corcept has right to sublease additional space under certain circumstances.","Sublease creates a direct financial obligation but no new debt or financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239392,"accession_number":"0001628280-24-005048","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q4 revenue $135.4M (+31% YoY); reiterates FY2024 guidance $600-630M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $135.4M (+31% YoY); net income $31.4M ($0.28 diluted EPS) vs $16.6M in Q4 2022.","Full-year 2023 revenue $482.4M (+20% YoY); net income $106.1M ($0.94 diluted EPS).","Cash and investments $425.4M; 2024 revenue guidance reiterated at $600-$630M.","NDA for relacorilant in Cushing's expected Q2 2024; GRACE results Q2; CATALYST shows 24% hypercortisolism prevalence in first 700 patients.","ROSELLA ovarian cancer trial and DAZALS ALS trial results expected by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":482375000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239391,"accession_number":"0001193125-24-003933","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Corcept reports Q4 2023 revenue $135.4M (+31% YoY); guides 2024 rev $600-630M; announces $200M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $135.4M, up 31% YoY from $103.1M; full year $482.4M, up 20% from $401.9M.","2024 revenue guidance $600-630 million; cash and investments $425.4M at Dec 31, 2023.","Board authorized $200M stock repurchase program; effective Jan 10, 2024.","Results are preliminary, unaudited, and subject to audit adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":482375000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239390,"accession_number":"0001193125-24-000247","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Court finds Teva does not infringe Corcept's Korlym patents; Corcept plans appeal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["District of New Jersey ruled Teva does not infringe Corcept's U.S. Patents 10,195,214 and 10,842,800.","Patents cover methods of safely administering Korlym with strong CYP3A4 inhibitors.","CEO Joseph Belanoff called decision disappointing and based on legal and factual errors.","Corcept will pursue a vigorous appeal; believes patents expanded treatment options for Cushing's syndrome.","FDA had added the patented methods to Korlym's prescribing instructions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256923,"accession_number":"0001193125-23-292621","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Corcept amends bylaws to strengthen director nomination and meeting rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board can postpone, reschedule or cancel annual meetings even after notice has been sent to stockholders.","Enhanced requirements for stockholder nominations and proposals; must comply with Rule 14a-19 and attend the meeting.","Proxy card color rule: white cards reserved for Board; any other solicitation must use a different color.","Eliminated requirement to make stockholder list available at meetings, aligning with recent Delaware law changes.","Amendments effective December 5, 2023; govern meeting procedures and proxy solicitation mechanics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256922,"accession_number":"0001628280-23-035979","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q3 revenue $123.6M (+22% YoY); raises FY 2023 guidance to $470-$480M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $123.6M (+22% YoY); net income $31.4M ($0.28 diluted EPS) vs $34.6M ($0.30) in Q3 2022.","FY 2023 revenue guidance raised to $470-$480M from previous $455-$470M.","Cash and investments $414.8M at Sept 30, up from $363.3M end of prior quarter.","GRACE Phase 3 enrollment complete; NDA for relacorilant in Cushing's expected Q2 2024.","Key 2024 trial readouts: GRADIENT (mid-2024), ROSELLA, DAZALS (year-end 2024), CATALYST prevalence (Q1 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":346970000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274250,"accession_number":"0001628280-23-026757","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q2 revenue $117.7M (+14% YoY); raises FY revenue guidance to $455-470M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $117.7M, up 14% YoY; net income $27.5M ($0.25 diluted EPS) vs $27.4M ($0.24) in Q2 2022.","Raises FY 2023 revenue guidance to $455-470M from $435-455M; cash $363.3M.","Repurchased 6.6M shares for $145.4M in April 2023.","Clinical: GRACE Phase 3 enrollment complete; relacorilant NDA submission expected Q2 2024.","ROSELLA ovarian cancer trial enrollment on track to complete by end of 2023; Phase 2b NASH trial to start Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":223369000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291456,"accession_number":"0001628280-23-019588","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Corcept Therapeutics stockholders approve officer exculpation charter amendment at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to certificate of incorporation to allow officer exculpation under Delaware law.","All nine management director nominees were elected to serve until 2024 annual meeting.","Ratified Ernst & Young as independent registered public accounting firm for fiscal year 2023.","Advisory vote on executive compensation approved; board will hold annual say-on-pay votes through at least 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291455,"accession_number":"0001628280-23-015219","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q1 revenue $105.7M (+13% YoY); raises FY2023 guidance to $435-455M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $105.7M vs $93.7M Q1 2022; net income $15.9M ($0.14 diluted EPS) vs $22.8M ($0.20) YoY.","Raised 2023 revenue guidance to $435-455M from prior $430-450M.","Cash and investments $465.1M at March 31, 2023; repurchased 6.6M shares for $145.4M in April 2023.","Operating expenses rose to $90.8M from $66.9M on increased clinical trial and commercial spending.","NDA submission for relacorilant in Cushing's syndrome planned first half 2024; Phase 3 GRACE enrollment near completion."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":105654000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312263,"accession_number":"0001628280-23-005562","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept reports Q4 revenue $103.1M, FY 2022 revenue $401.9M; guides 2023 revenue $430-450M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $103.1M vs $98.8M Q4 2021; FY revenue $401.9M vs $366.0M.","FY 2022 diluted EPS $0.87 vs $0.89 in 2021; net income $101.4M vs $112.5M.","Cash and investments $436.6M at Dec 31, 2022, up from $335.8M year-end 2021.","NDA for relacorilant in Cushing's syndrome expected Q1 2024; GRACE enrollment closing.","Phase 3 ROSELLA (ovarian cancer) and Phase 2 DAZALS (ALS) enrolling; miricorilant Phase 1b NASH data mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":401858000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312262,"accession_number":"0001193125-23-034374","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept reaches preliminary $14M settlement in securities class action; insurer to pay","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement of Melucci v. Corcept case in Northern District of California.","One-time $14.0M payment fully covered by Corcept's insurers.","Case was pending since 2019; settlement is preliminary subject to court approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330838,"accession_number":"0001193125-22-300535","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept settles patent litigation with Hikma; generic Korlym entry set for October 2034","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement with Hikma resolves patent litigation over generic Korlym in District of New Jersey.","Hikma granted right to sell generic Korlym in U.S. beginning October 1, 2034 or earlier under customary conditions.","Similar patent litigation against Teva Pharmaceuticals USA remains pending.","Settlement subject to court consent judgment and FTC/DOJ review.","CEO Belanoff noted the settlement allows focus on growing Korlym and developing cortisol modulator pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330837,"accession_number":"0001628280-22-028184","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q3 revenue $101.7M (+5.8% YoY); tightens 2022 guidance to $400-410M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS $0.30 vs $0.24 in Q3 2021; net income $34.6M.","Tightened FY 2022 revenue guidance to $400-410M from prior range.","Cash and investments $401.2M at Sept 30, up from $382M at June 30.","Operating expenses $69.8M (+16.5% YoY) on clinical and commercial expansion.","Enrolling pivotal Phase 3 ROSELLA trial in ovarian cancer; GRATITUDE AIWG data expected Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":298802000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348341,"accession_number":"0001193125-22-249225","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2022-09-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Corcept extends exclusive specialty pharmacy agreement for Korlym with Optime to March 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment extends Optime's exclusive dispensing services for Korlym to March 31, 2024.","No financial terms disclosed; original agreement from August 2017.","Optime remains sole specialty pharmacy for Korlym in the United States."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348340,"accession_number":"0001628280-22-020614","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q2 revenue $103.4M (up 13% YoY); EPS $0.24; reiterates FY22 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $103.4M (Q2 2021: $91.6M); diluted EPS $0.24 vs $0.21.","Reiterated FY2022 revenue guidance of $400-$430 million.","Cash and investments $382.0 million, up $13.9 million from Q1 2022.","Initiated Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.","Expects Phase 2 AIWG (miricorilant) and NASH data in Q4 2022; NDA submission for relacorilant in Cushing's in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":197074000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365036,"accession_number":"0001628280-22-016073","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Corcept shareholders reject amended 2012 incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected, with votes ranging from 70.6M to 83.9M in favor.","Amended 2012 Incentive Award Plan not approved: 39.2M for, 44.6M against, 0.4M abstain.","Ratification of Ernst & Young as auditor for FY2022 approved with 96.4M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365035,"accession_number":"0001628280-22-012652","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q1 revenue $93.7M (+18% YoY); reiterates FY2022 guidance $400-430M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS $0.20 vs $0.18 YoY; cash & investments $368.1M (up $32.3M in Q1).","Phase 3 trial of relacorilant in platinum-resistant ovarian cancer to start this quarter.","GRATITUDE I/II data for miricorilant in antipsychotic weight gain expected Q4 2022.","Relacorilant NDA for Cushing's syndrome now expected H2 2023 (pandemic delays).","Operating expenses $66.9M (+12% YoY) on expanded R&D and legal costs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":93688000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384637,"accession_number":"0001628280-22-002707","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q4 revenue $98.8M, net income $32.1M; guides 2022 rev $400-430M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $98.8M (+15% YoY); FY2021 revenue $366M (+3.4% from $353.9M).","Q4 GAAP net income $32.1M (vs $26M); FY GAAP net income $112.5M (vs $106M). Non-GAAP Q4 $42.6M.","2022 revenue guidance $400-430M, implying 9-17% growth.","Repurchased 10M shares for $207.5M in Q4; cash+investments $335.8M.","Clinical: ovarian cancer Phase 3 start Q2 2022; AIWG Phase 2 data Q4 2022; NDA for Cushing's Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":365978000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402505,"accession_number":"0001193125-21-350898","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2021-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Corcept wins patent appeal, discloses DOJ subpoena on Korlym sales, extends tender offer to Dec 15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Federal Circuit affirmed PTAB decision upholding validity of '214 patent (expires 2037) against Teva challenge.","Received HIPAA subpoena from NJ USAO regarding Korlym sales and HCP payments; investigating potential criminal/civil violations; Corcept not a defendant.","Extended tender offer expiration to Dec 15, 2021; 8,282,336 shares tendered to date; condition of at least 3M shares tendered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402504,"accession_number":"0001628280-21-021481","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q3 revenue $96.1M (+11% YoY); narrows 2021 guide to $365-375M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.24 vs $0.17 YoY; non-GAAP diluted EPS $0.30 vs $0.24.","Cash and investments $495.2M, up from $471.6M at June 30; repurchased 1.2M shares in Q3.","Plans Phase 3 trial in recurrent platinum-resistant ovarian cancer in Q1 2022; updated OS data expected Q1 2022.","Phase 2 NASH data to be presented at AASLD Nov 12-15; Phase 1b dose-finding trial initiated.","Relacorilant NDA submission for Cushing's syndrome expected Q2 2023; GRACE and GRADIENT trials enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":267156000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421452,"accession_number":"0001193125-21-244963","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2021-08-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Corcept Therapeutics appoints William Guyer as CDO; CMO Andreas Grauer departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andreas Grauer separated as CMO effective Aug 10, 2021, becomes senior medical advisor to assist transition.","William Guyer, formerly SVP at Gilead Sciences, appointed CDO effective Aug 16, 2021.","Guyer brings ~30 years of experience; led global Medical Affairs at Gilead, involved in multiple drug launches.","Separation agreement provides Grauer one-year salary continuation, COBRA coverage, and quarterly housing allowance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421451,"accession_number":"0001628280-21-014888","cik":1088856,"company_name":"CORCEPT THERAPEUTICS INC","ticker":"CORT","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Corcept Q2 revenue $91.6M; GAAP EPS $0.21; reiterates 2021 guidance $355-385M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $91.6M (+3.4% YoY); GAAP diluted EPS $0.21 vs $0.23; non-GAAP EPS $0.30 vs $0.32.","Cash and investments $471.6M, +$16.8M from Q1; repurchased 1.4M shares for $30.8M.","2021 revenue guidance reaffirmed at $355-385M; CEO cites easing COVID restrictions driving growth.","Phase 3 pivotal trial of relacorilant in platinum-resistant ovarian cancer expected to start Q1 2022.","GRACE Phase 3 trial for relacorilant in Cushing's syndrome continues; NDA submission planned Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":171025000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7154983746.901922,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}